Effect of Bacterial and Host Factors on Helicobacter Pylori Eradication Therapy

Overview

Journal Expert Opin Ther Targets

Publisher Informa Healthcare

Specialty Pharmacology

Date 2015 Aug 7

PMID 26245678

Citations 11

Authors

Takahiro Uotani

Muhammad Miftahussurur

Yoshio Yamaoka

Affiliations

Soon will be listed here.

Abstract

Introduction: A clearer understanding of the factors affecting the cure rate of Helicobacter pylori infection might lead to the development of novel prevention strategies and therapeutic targets.

Areas Covered: This review covers two important issues that affect the eradication of H. pylori: bacterial and host factors. Several virulence factors have been shown to be predictors for gastroduodenal diseases. Successful treatment of H. pylori infection also depends on host genetic factors such as CYP2C19 and IL-1B. The latest evidence on host genetic factors is discussed.

Expert Opinion: The authors identify three main targets for achieving effective eradication therapy. The first therapeutic target is to identify counter measures for antibiotic-resistant H. pylori strains. Thus, antibiotic susceptibility should be checked in all patients, ideally, before the start of eradication treatment. The second therapeutic target is the inhibition of acid suppression. Maintaining a high intragastric pH for 24 h increases the effectiveness of some antibiotics and the eradication effects for H. pylori. The third therapeutic target is to identify high-risk groups; the CYP2C19 and IL-1B polymorphisms are candidates for significant risk factors. A personalized medical approach will likely increase the cure rate of H. pylori infection.

Citing Articles

Unveiling Novel Urease Inhibitors for : A Multi-Methodological Approach from Virtual Screening and ADME to Molecular Dynamics Simulations.

Valenzuela-Hormazabal P, Sepulveda R, Alegria-Arcos M, Valdes-Munoz E, Rojas-Perez V, Gonzalez-Bonet I Int J Mol Sci. 2024; 25(4).

PMID: 38396647 PMC: 10888695. DOI: 10.3390/ijms25041968.

Application of a WeChat-based mini-app as a patient reminder in Helicobacter pylori eradication: a prospective multi-center randomized controlled study.

Sun K, Chen Y, Wang Z, Liu Y, Pan Y, Mao X BMC Gastroenterol. 2022; 22(1):520.

PMID: 36522612 PMC: 9756606. DOI: 10.1186/s12876-022-02614-1.

Involvement of in Preoperative Gastric Findings on a Bariatric Population.

Garcia-Gomez-Heras S, Fernandez-Acenero M, Gonzalez G, Bolanos-Munoz M, Franco-Rodriguez R, Paredes-Gonzalez J Int J Environ Res Public Health. 2022; 19(15).

PMID: 35897458 PMC: 9332016. DOI: 10.3390/ijerph19159088.

Eradication Efficacy of Therapy Based on the Antimicrobial Susceptibility in Children with Gastritis and Peptic Ulcer in Mekong Delta, Vietnam.

Le L, Nguyen T, Nguyen N, Nguyen Y, Nguyen H, Nguyen L Children (Basel). 2022; 9(7).

PMID: 35884002 PMC: 9324491. DOI: 10.3390/children9071019.

Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.

Roszczenko-Jasinska P, Wojtys M, Jagusztyn-Krynicka E Appl Microbiol Biotechnol. 2020; 104(23):9891-9905.

PMID: 33052519 PMC: 7666284. DOI: 10.1007/s00253-020-10945-w.

References

Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto K . Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. Helicobacter. 2014; 19(4):312-8. DOI: 10.1111/hel.12128. View

Cover T, Blanke S . Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. 2005; 3(4):320-32. DOI: 10.1038/nrmicro1095. View

Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M . Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007; 12(4):317-23. DOI: 10.1111/j.1523-5378.2007.00508.x. View

Hussein N . The association of dupA and Helicobacter pylori-related gastroduodenal diseases. Eur J Clin Microbiol Infect Dis. 2010; 29(7):817-21. DOI: 10.1007/s10096-010-0933-z. View

Wilson A, Symons J, McDowell T, McDevitt H, Duff G . Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997; 94(7):3195-9. PMC: 20345. DOI: 10.1073/pnas.94.7.3195. View

Grad Y, Lipsitch M, Aiello A . Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol. 2011; 175(1):54-9. PMC: 3244610. DOI: 10.1093/aje/kwr288. View

Osato M, Reddy R, Reddy S, Penland R, Malaty H, Graham D . Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001; 161(9):1217-20. DOI: 10.1001/archinte.161.9.1217. View

Lanas A, Garcia-Gonzalez M, Santolaria S, Crusius J, Serrano M, Benito R . TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. Genes Immun. 2002; 2(8):415-21. DOI: 10.1038/sj.gene.6363798. View

Zagari R, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F . Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2006; 56(4):475-9. PMC: 1856863. DOI: 10.1136/gut.2006.102269. View

10.

Kim N, Kim J, Kim C, Park Y, Lee D, Kim J . Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol. 2006; 40(8):683-7. DOI: 10.1097/00004836-200609000-00004. View

11.

Yea S, Yang Y, Jang W, Lee Y, Bae H, Paik K . Association between TNF-alpha promoter polymorphism and Helicobacter pylori cagA subtype infection. J Clin Pathol. 2001; 54(9):703-6. PMC: 1731516. DOI: 10.1136/jcp.54.9.703. View

12.

Treiber G, Wittig J, Ammon S, Walker S, van Doorn L, Klotz U . Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med. 2002; 162(2):153-60. DOI: 10.1001/archinte.162.2.153. View

13.

Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F . Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2002; 17(1):99-109. DOI: 10.1046/j.1365-2036.2003.01396.x. View

14.

De Boer W, Driessen W, JANSZ A, Tytgat G . Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet. 1995; 345(8953):817-20. DOI: 10.1016/s0140-6736(95)92962-2. View

15.

Hatakeyama M . Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004; 4(9):688-94. DOI: 10.1038/nrc1433. View

16.

Furuta T, Ohashi K, Kosuge K, Zhao X, Takashima M, Kimura M . CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999; 65(5):552-61. DOI: 10.1016/S0009-9236(99)70075-5. View

17.

Crabtree J, Taylor J, Wyatt J, Heatley R, Shallcross T, Tompkins D . Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet. 1991; 338(8763):332-5. DOI: 10.1016/0140-6736(91)90477-7. View

18.

Grayson M, Eliopoulos G, Ferraro M, Moellering Jr R . Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1989; 8(10):888-9. DOI: 10.1007/BF01963775. View

19.

Tarlow J, Blakemore A, Lennard A, Solari R, Hughes H, Steinkasserer A . Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993; 91(4):403-4. DOI: 10.1007/BF00217368. View

20.

Hirayama Y, Kawai T, Otaki J, Kawakami K, Harada Y . Prevalence of Helicobacter pylori infection with healthy subjects in Japan. J Gastroenterol Hepatol. 2014; 29 Suppl 4:16-9. DOI: 10.1111/jgh.12795. View